Value
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 2.4 |
| P/S | 4.4 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 4.4 |
| PEG | 4.3 |
| Analyst target | 4.0 |
- ▸Forward P/E: 28.0x
- ▸PEG: 2.21
EW · Why this verdict
Why Edwards Lifesciences Corporatio (EW) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.5/10
ConfidenceHIGH
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Gross and operating margins both score at their maximum level with a Piotroski F-Score of 8 out of 9, placing this among the highest-quality franchises in the medical device space and providing meaningful cushion against temporary revenue setbacks. Quality breakdown | Margins noted as strong at the 17% level are maintained or improved over the next 12 months, and the Piotroski F-Score remains at 7 or above, confirming durable financial health. | →Stable |
| CounterA product revenue concentration of 74% in a single franchise means any clinical complication, regulatory action, or competitive entry affecting that category could compress these margins sharply, with limited business diversification to absorb the impact. | ||
With approximately 74% of revenues concentrated in one product category and 58% in a single geography, any clinical setback, reimbursement change, or competitive displacement in the core franchise would have an outsized impact on overall results with no material offset from other lines of business. Bear case | Revenue from the leading product category declines to represent less than 65% of total sales within 2 fiscal years as the broader portfolio grows, reducing single-product dependency. | →Stable |
| CounterThe bull case highlights a high-quality business, and best-in-class margins among peers suggest the leading product has established durable commercial economics that may limit the likelihood of rapid substitution. | ||
Price momentum has fallen to 3.2, below the 4.5 acceptable threshold, while volume is flowing out of the stock — a deteriorating technical picture at a forward multiple of 25.6x means a rich multiple can persist absent a catalyst but creates meaningful downside if expectations are missed. Engine gate (failed) | Price momentum recovers above the 4.5 threshold and the stock closes above the near-term price target of $87.23 for 3 consecutive weeks, confirming both technical and fundamental improvement. | →Stable |
| CounterThree of the last four quarters produced positive earnings surprises averaging approximately 5.3%, and the stock remains above its 200-day moving average — the fundamental delivery record may eventually reassert itself over the near-term technical softness. | ||
Three earnings beats in the last four quarters with an average positive surprise of approximately 5.3% demonstrate a pattern of outperforming consensus that provides a partial offset to the valuation and momentum headwinds facing the stock. Earnings | The beat streak extends to 4 of 5 quarters with average positive surprise maintained above 3%, sustaining the fundamental credibility that supports the premium multiple. | →Stable |
| CounterThe one miss in the sequence came in at -6.3% below estimate, showing the earnings record is not immune to setbacks; a second miss could trigger a multiple compression event given the already thin margin between price and target. | ||
Gross and operating margins both score at their maximum level with a Piotroski F-Score of 8 out of 9, placing this among the highest-quality franchises in the medical device space and providing meaningful cushion against temporary revenue setbacks.
→StableQuality breakdown
- Expectation
- Margins noted as strong at the 17% level are maintained or improved over the next 12 months, and the Piotroski F-Score remains at 7 or above, confirming durable financial health.
CounterA product revenue concentration of 74% in a single franchise means any clinical complication, regulatory action, or competitive entry affecting that category could compress these margins sharply, with limited business diversification to absorb the impact.
With approximately 74% of revenues concentrated in one product category and 58% in a single geography, any clinical setback, reimbursement change, or competitive displacement in the core franchise would have an outsized impact on overall results with no material offset from other lines of business.
→StableBear case
- Expectation
- Revenue from the leading product category declines to represent less than 65% of total sales within 2 fiscal years as the broader portfolio grows, reducing single-product dependency.
CounterThe bull case highlights a high-quality business, and best-in-class margins among peers suggest the leading product has established durable commercial economics that may limit the likelihood of rapid substitution.
Price momentum has fallen to 3.2, below the 4.5 acceptable threshold, while volume is flowing out of the stock — a deteriorating technical picture at a forward multiple of 25.6x means a rich multiple can persist absent a catalyst but creates meaningful downside if expectations are missed.
→StableEngine gate (failed)
- Expectation
- Price momentum recovers above the 4.5 threshold and the stock closes above the near-term price target of $87.23 for 3 consecutive weeks, confirming both technical and fundamental improvement.
CounterThree of the last four quarters produced positive earnings surprises averaging approximately 5.3%, and the stock remains above its 200-day moving average — the fundamental delivery record may eventually reassert itself over the near-term technical softness.
Three earnings beats in the last four quarters with an average positive surprise of approximately 5.3% demonstrate a pattern of outperforming consensus that provides a partial offset to the valuation and momentum headwinds facing the stock.
→StableEarnings
- Expectation
- The beat streak extends to 4 of 5 quarters with average positive surprise maintained above 3%, sustaining the fundamental credibility that supports the premium multiple.
CounterThe one miss in the sequence came in at -6.3% below estimate, showing the earnings record is not immune to setbacks; a second miss could trigger a multiple compression event given the already thin margin between price and target.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Edwards Lifesciences carries best-in-class margins and a consistent earnings beat pattern, but a forward multiple of 25.6x combined with price momentum below the acceptable threshold, a 74% product concentration in a single franchise, and only about 1% headroom to the near-term price target create a risk/reward profile that does not justify adding to the position at current levels.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 3.5 |
| ROA | 5.5 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 8.7 |
| Current ratio | 8.6 |
| FCF quality | 6.1 |
| Moat | 6.4 |
| Rule of 40 | 5.5 |
| Piotroski F | 8.9 |
- ▸Strong margins: 17%
- ▸Strong Piotroski F-Score: 8/9
Growth
5.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 6.7 |
| EPS growth | 3.6 |
Momentum
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.3 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 1.1 |
- ▸Overbought (RSI 74)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.0 |
| Analyst rating | 7.5 |
| Price target | 5.5 |
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Insider selling (low materiality) — $7,918,479 (0.015% of mkt cap)
Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.4 |
| quality rank | 7.6 |
| growth rank | 6.6 |
- ▸Best-in-class margins
Technical
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.1 |
| 52w position | 10.0 |
Risk (lower is worse)
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.8 |
| days to cover | 8.5 |
| volatility | 5.9 |
| put call | 7.1 |
| implied vol | 6.3 |
| beta | 7.9 |
| debt equity | 0.0 |
- ▸Concentration risks: 3 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 5.2 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING).
Engine technical detail
verdict_path:
L4:PATH_F_SELL|L3:NEWS_MOD=+2Passed (6)
- MOMENTUM:6.9>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:20d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.6=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.61
Upside
-7.2%
Downside
11.9%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 20d with 3/4 beat streak
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 4.0 below the 5.4 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Quality at 7.3) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.6=NEGATIVE) reinforce the read. Current asymmetry R:R is -0.61 — supplementary context, not the trigger for this path.
The strongest dimensions are Quality at 7.3, Momentum at 6.9, and Risk (lower is worse) at 6.4; the weakest are Technical at 3.4, Value at 3.4, and Peer rank at 5.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.61 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Best In Class Margins Quality
Trip ifPiotroski F-Score falls below 6 out of 9 for 2 consecutive quarters.
- P2Single Product Concentration Risk
Trip ifRevenue from the leading product category falls below 65% of total revenues for 2 consecutive fiscal years.
- P3Rich Valuation Weak Momentum
Trip ifPrice momentum rises above 4.5 and stock holds above $87.23 for 3 consecutive weeks.
- P4Consistent Earnings Beat Pattern
Trip ifEPS surprise falls below 0 for 2 consecutive quarters, breaking the consistent beat pattern that provides a partial offset to valuation and momentum headwinds.